Skip to main content

29 September 2020

A necessary transition: why viral vector production for gene therapy needs to evolve

OXGENE

Interview/Cell & Gene Therapy Insights/29 September 2020/Issue 2020; 6(8), 1163–1170

Download PDF – 1.4 MB

Abstract

Ryan founded Oxford Genetics in 2011, after earning a first class degree in genetics and a PhD from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™ that allowed researchers – for the first time – to assemble complex sections of DNA as simply as ‘molecular Lego’. Ryan used his background in genetic engineering and virology to guide and grow the business through a series of strategic changes that explored how further development of the SnapFast™ platform through in house research and development could help overcome multiple challenges in the development of new biologics.

This culminated in a rebrand to OXGENE in 2019, as the company redefined itself as a leading solutions provider, using a combination of proprietary technologies to address multiple pinch-points on the journey through design, discovery, development and manufacture of a novel biologic.

Download the resource to continue reading.
×